A randomized controlled trial of a digital lifestyle intervention involving postoperative patients with colorectal cancer
Abstract
Few studies have investigated quality of life (QoL) improvements in patients with colorectal cancer or the benefits of digital healthcare interventions. This randomized controlled trial assessed the impact of mobile applications on postoperative QoL in patients scheduled for curative surgery for colorectal cancer. Patients were randomized into three intervention groups (each using a different mobile application for postoperative lifestyle management) and a control group. QoL was evaluated using the European Quality of Life-5 Dimensions (EQ-5D), with physical and metabolic parameters and fat/muscle areas measured preoperatively, and every six months postoperatively. At six months, no significant differences in the EQ-5D scores from baseline were observed across groups. Intervention Group C showed a significant increase in skeletal muscle area compared to the control group (P = 0.046). Overall, mobile application use had a minimal effect on postoperative health-related QoL, warranting further research on their efficacy and compliance rates. Trial registration: CRIS.nih.go.kr: KCT0005447. Registration date: June 23, 2020.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
- Endogenous Akt Activity Promotes Virus Entry and Predicts Efficacy of Novel Chimeric Orthopoxvirus in Triple-Negative Breast Cancer
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.